Ultime notizie per Lyell Immunopharma (NASDAQ:LYEL) Azioni

Lyell Immunopharma

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Lyell Immunopharma Inc

<a href="https://www.benzinga.com/real-estate/24/11/41876775/u-s-homebuyers-are-now-56-on-average-as-younger-generations-struggle-with-wildly-unaffordable-market-housing-expert-warns">Housing is unaffordable</a>. Essentials cost more than ever. And despite working full time — sometimes more — millions of Americans still feel like they're one flat tire away from financial disaster.
Warren Buffett talked about this exact problem 10 years ago. Not as a warning about what might happen — but as a plain description of what already was.
"There's been millions that have lived the dream," he said during a <a href="https://youtu.be/353OLA_VOFw?si=eigJ84g015jloCn6">2015 interview with PBS NewsHour</a>. "But there's been an American nightmare that has accompanied that."
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Buffett wasn't describing people who gave up or checked out. He was talking about the ones who did everything society told them to do and still couldn't get ahead.
"That's where people that equally have <a href="https://www.benzinga.com/25/04/44855242/charlie-munger-once-highlighted-how-warren-buffetts-lifelong-learning-made-berkshire-hathaways-success-possible-and-the-crucial-lesson-you-can-take-from-it">tried to get education</a> and worked hard and had good habits have found themselves living a life that's been on the edge throughout their entire lives — and the same for their children."
It was an election year, and Buffett said he wanted candidates to address it — not in theory, but in concrete action.
"I would like to hear any candidate say they felt about that and what they intended to do about it. It's got to be a big issue."
In Buffett's view, one of the best tools wasn't a minimum wage hike. It was the Earned Income Tax Credit, a benefit that boosts pay for low- to moderate-income workers through the tax system.
"I think the Earned Income Credit is by far the most useful tool to really minimize poverty in this country," he said. "It does not interfere with the market system, and it could be geared in various ways to reward work."
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
His logic was simple: if someone's working a full-time job, they shouldn't be living in poverty. The EITC, he believed, was the best way to ensure they wouldn't — without putting pressure on employers to solve it alone.
"You want people to feel good about what they do in life," Buffett said. A "reasonable job," paired with a substantial tax credit, was the combination he backed.
He also pointed out that economic mobility doesn't start in adulthood. According to him, it starts in preschool. "In many cases, people don't have a fair shot by the time they're four or five years old."
At the time, he called <a href="https://www.benzinga.com/startups/25/01/43101102/elon-musk-the-richest-man-in-the-world-is-estimated-to-earn-over-23-million-every-single-hour-of-the-day-heres-how-hes-spending-it">the wealth imbalance</a> "out of whack." While the Forbes 400 had seen their collective net worth surge by 2,300% since the 1980s, Buffett noted that the bottom 20% of Americans had barely seen income grow at all — less than 1%.
"You expect unequal results in a market economy, <a href="https://www.benzinga.com/personal-finance/25/04/44659151/bill-and-melinda-gates-agreed-its-not-fair-we-have-so-much-wealth-and-say-their-money-opens-doors-most-people-will-never-get-through">very unequal</a>," he said. "But you really shouldn't have an economy with over $50,000 in GDP per person and have lots of people living in poverty who are willing to work. I mean, that does not make sense."&nbsp;
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
A decade later, it still doesn't. GDP per capita is pushing $90,000 and yet, the bottom half of Americans still hold just 2.5% of the country's wealth.
Despite the passage of time, the central issue Buffett laid out remains largely untouched. The tax credit he described as "by far the most useful tool" continues to fly under the radar, while the structural problems he highlighted — from wages to early childhood gaps — still show up in headlines and household budgets.
The nightmare didn't disappear. If anything, people just stopped calling it that out loud.
Read Next:
<ul>
<li>With high-demand properties in the Midwest, Bam Capital has delivered 2.46x equity multiples in just over 3 years. No losses. No missed payments. <a href="https://www.benzinga.com/money/investing-in-the-midwest-why-multifamily-real-estate-is-a-winning-strategy">Learn more about becoming an investor today</a>. </li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Warren Buffett Says Millions Are Trapped Living An 'American Nightmare' — But Proposes A Tool 'Far More Useful' Than Raising Minimum Wage

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

KWESW

First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) has outperformed the market over the past 5 years by 24.63% on an annualized basis producing an average annual return of 37.56%. Currently, First Citizens BancShares has a market capitalization of $23.47 billion. 
Buying $1000 In FCNCA: If an investor had bought $1000 of FCNCA stock 5 years ago, it would be worth $5,185.91 today based on a price of $1734.53 for FCNCA at the time of writing.
<h3>First Citizens BancShares's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745364614_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

FCNCA

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are climbing in after-hours trading Tuesday despite the missing earnings estimates for the first quarter. CEO Elon Musk boosted investor sentiment with some announcements during the company&#8217;s conference call <a href="https://www.benzinga.com/news/earnings/25/04/44937440/tesla-q1-misses-estimates-as-tariff-pressures-weigh-on-outlook-lower-cost-evs-still-on-track">following the print. </a>
What To Know: Tesla reported first-quarter revenue of $19.34 billion, missing a Street consensus estimate of $21.35 billion, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>. 
Tesla&#8217;s first-quarter earnings were 27 cents per share, down 40% year-over-year and missing a Street consensus estimate of 31 cents per share.
Read Next:<a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable"> UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;</a>
Benzinga users correctly predicted Tesla would miss consensus estimates in the first quarter in a poll conducted before the print.
The poll results were:
<ul>
<li>Miss: 68%</li>
<li>Beat: 19%</li>
<li>Inline: 11%</li>
</ul>
Benzinga Pro users also predicted some major announcements from Musk on the earnings call, including a reduction in the CEO&#8217;s time spent working at the Department of Government Efficiency. 
User PrudentOpportunity29 posted a prediction in the Benzinga Pro Lounge at 4:05 p.m. ET that Musk would announce an exit from DOGE and would pump the Robotaxi approval. 
The user was on point with both statements: Musk announced he will be spending far less time at DOGE beginning next month and the Austin robotaxi launch remains on schedule for June 2025.
TSLA Price Action: According to data from Benzinga Pro, Tesla stock was up 5.62% at $51.35 after-hours at the time of publication Tuesday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/04/44903087/amazon-stock-downgraded-price-target-slashed-as-tariffs-create-uncertainty">Amazon Stock Downgraded, Price Target Slashed As Tariffs Create Uncertainty&nbsp;</a></li>
</ul>
Photo: Shutterstock

Earnings

Management

After-Hours Center

Movers

Tech

TSLA

Benzinga Readers' Predictions For Tesla Q1 Earnings Results, Musk's Announcements

Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) has outperformed the market over the past 15 years by 5.39% on an annualized basis producing an average annual return of 15.8%. Currently, Advanced Micro Devices has a market capitalization of $143.62 billion. 
Buying $100 In AMD: If an investor had bought $100 of AMD stock 15 years ago, it would be worth $900.42 today based on a price of $88.40 for AMD at the time of writing.
<h3>Advanced Micro Devices's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745363719_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Advanced Micro Devices 15 Years Ago Would Be Worth This Much Today

U.S. health officials announced Tuesday that the Food and Drug Administration will phase out petroleum-based synthetic food dyes by the end of 2026 in a major shift for <a href="https://www.benzinga.com/government/regulations/25/01/43011207/fda-bans-red-dye-no-3-effective-january-2027-cites-cancer-risks-food-stocks-to-watch">the nation's food industry.</a>
"For the last 50 years, we have been running one of the largest uncontrolled scientific experiments in the world on our nation's children without their consent," FDA Commissioner Marty Makary said at a news conference.
Read Next: <a href="https://www.benzinga.com/25/04/44935272/tesla-reports-q1-after-the-bell-68-expect-the-company-to-miss-analysts-estimates">Will Tesla Beat The Street? 68% Expect Something Markets May Not Be Ready For</a>
Artificial color additives such as Red 40, Yellow 5 and Blue 1 are used to give products like cereals, chips and sports drinks their vivid colors, but concerns about their safety have been growing for years. Health advocates have cited research linking these dyes to hyperactivity and other neurobehavioral issues in children, though the FDA maintains most children do not experience adverse effects from consuming them.
The new regulations will require major food manufacturers like PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) and Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) to reformulate products and transition to natural color alternatives. 
Industry representatives have argued that there is insufficient evidence to justify a ban, but the FDA is moving forward with a national standard and clear timeline for the transition.
The eight synthetic dyes targeted for elimination include Red No. 40, Red No. 3, Yellow No. 5, Yellow No. 6, Blue No. 1, Blue No. 2, Green No. 3, and possibly Orange B or Citrus Red No. 2. Red No. 3, already linked to cancer in laboratory animals, was previously scheduled for a federal ban by January 2027.&nbsp;
The FDA is also expected to authorize additional natural color additives and accelerate the review of others to support the industry's transition.
"For companies that are currently using petroleum-based red dye, try watermelon juice or beet juice. For companies currently combining petroleum-based yellow chemical and red dyes together, try carrot juice," Makary said. 
Health and Human Services Secretary Robert F. Kennedy Jr., who oversees the FDA, has made eliminating artificial dyes a priority, citing the need to address chronic disease and improve children's health as part of his "Make America Healthy Again" campaign.
"We are betraying our children by letting these industries poison them,&#8221; Kennedy said at a Trump campaign rally in November 2024.&nbsp;
General Mills Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) may have seen the ban coming as the mega-manufacturer of processed foods released a statement last November after President Donald Trump announced Kennedy as his choice for the position  
&#8220;Because this is always an evolving space, we work in close partnership with policymakers on this issue,&#8221; General Mills said in the statement. &#8220;We will engage with federal regulators as they consider any additional changes they may propose.&#8221;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/04/44903087/amazon-stock-downgraded-price-target-slashed-as-tariffs-create-uncertainty">Amazon Stock Downgraded, Price Target Slashed As Tariffs Create Uncertainty&nbsp;</a></li>
</ul>
Photo: Shutterstock

Government

Regulations

Politics

RFK Jr. Will Phase Out Artificial Food Dyes By End Of 2026: What It Means For Pepsi, Coca-Cola, General Mills

Guy Fieri isn't handing out slices of his Flavortown fortune without a side of hard work and higher education.
In a <a href="https://www.foxnews.com/video/6342922469112">2023 interview with Fox News Digital</a>, the Food Network star made it clear that his sons won't be cruising into generational wealth just because dad built a nine-figure empire. "I told them the same thing my dad told me," Fieri said. "‘When I die, you can expect that I am going to die broke and you're going to be paying for the funeral.' And I told my boys, none of this that I've been building are you going to get, unless you come and take it from me."
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
At 57, Fieri has built one of the most successful brands in food television history — from "Diners, Drive-Ins and Dives" to multi-million-dollar endorsement deals and restaurant chains. His estimated net worth in 2025 sits at $100 million. But his kids? They're on their own unless they bring more than just good taste to the table.
And in true Guy fashion, he's borrowing a quote from another larger-than-life personality: Shaquille O'Neal.
"My son is a senior in high school getting ready to graduate," Fieri told Fox. "And he's like, ‘Dad, this is so unfair. I haven't even gone to college yet and you're already pushing that I gotta get an MBA.' He says, ‘Can I just get through college?' And I'm like — hey, Shaq said it best. Shaq said it about his kids one time, ‘If you want any of this cheese, <a href="https://www.benzinga.com/personal-finance/24/08/40658562/nba-legend-shaq-tells-his-kids-in-order-to-get-my-cheese-you-have-to-present-me-with-two-degrees">you got to get two degrees</a>.' Well, my two degrees mean postgraduate. So they're on their way."
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Shaq, now 53, has said in multiple interviews that his children won't see a dime unless they bring him at least two college degrees, and sometimes he raises the bar to three. "We ain't rich — I'm rich," <a href="https://www.benzinga.com/personal-finance/24/09/40943843/we-aint-rich-im-rich-nba-legend-shaq-says-his-daughters-and-sons-dont-get-equal-treatment-my-boy">he famously told them</a>. And in 2025, it's clear more celebrity parents are taking the same stance.
Fieri's nephew is studying entertainment law, aiming to become a big-time agent. His older son, Hunter, is working toward his MBA. Meanwhile, his younger son, Ryder, has already been warned: this won't be a free ride.
The approach reflects a generational shift — or maybe a generational speed bump. While millennials and Gen Z are <a href="https://www.benzinga.com/personal-finance/financial-advisors/24/10/41418601/great-wealth-transfer-poses-both-risks-and-opportunities-for-financial-adviso">poised to inherit as much as $84 trillion</a> over the coming decades in what's being called the "Great Wealth Transfer," not all parents are writing blank checks. Instead, some are setting conditions, demanding proof of ambition, education, or real-world hustle before they pass the torch (or the trust).
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
For Fieri, the goal isn't to be cold — it's to prepare. "You've got to go stake your claim and go figure out what you're going to do," he said. His message to his kids is simple: the money's real, but so is the expectation.
In an age where "nepo baby" talk dominates headlines, Fieri and Shaq are flipping the script. The cheese may be in the fridge — but the door only opens if you bring degrees.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/investing-in-the-midwest-why-multifamily-real-estate-is-a-winning-strategy">This investment company boasts a 33.85% internal rate of return (IRR) for its realized projects, allowing accredited investors to earn passive returns and avoid the headaches of being a landlord.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Food Network Star Guy Fieri's $100 Million Fortune Comes With Shaq-Inspired Rule For His Sons: 'If You Want This Cheese, You Got to Get Two Degrees'

Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) has outperformed the market over the past 5 years by 15.83% on an annualized basis producing an average annual return of 28.76%. Currently, Carrier Global has a market capitalization of $51.38 billion. 
Buying $100 In CARR: If an investor had bought $100 of CARR stock 5 years ago, it would be worth $365.97 today based on a price of $59.47 for CARR at the time of writing.
<h3>Carrier Global's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745361911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARR

Here's How Much $100 Invested In Carrier Global 5 Years Ago Would Be Worth Today

For several years, Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has been working on construction and plans for a California charging station that will house a diner and <a href="https://www.benzinga.com/news/24/03/37465922/teslas-la-supercharger-installs-first-movie-screen-for-drive-in-will-doge-payments-be-accepted">movie drive-in screen. </a>
Plans for that Supercharger location could be nearing completion, according to a new report.
What Happened: Tesla's <a href="https://www.benzinga.com/markets/cryptocurrency/22/02/25754907/tesla-restaurant-and-drive-in-theater-planned-for-q2-in-hollywood-and-could-accept-dogecoi">plans to have a diner </a>at its California Supercharger location could date back to trademarks filed several years ago for restaurant options at charging stations.
The company ended the fourth quarter with nearly 7,000 Supercharger locations and while some feature unique items like pools and food options, many are simply a place to charge electric vehicles.
The Hollywood Tesla Diner location could be close to opening, according to pictures shared on X by <a href="https://x.com/BLKMDL3/status/1914144046601347352">BLKMDL3 </a>and a report from <a href="https://www.teslarati.com/teslas-hollywood-diner-is-finally-getting-close-to-opening/">Teslarati</a>.
According to the report, the Supercharger location has a fully paved parking lot and the superchargers are now lit up.
Tesla began construction on the project in 2023 and its progress has taken longer than most Tesla Superchargers given the scope of the project and added amenities.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/01/43321103/tesla-q4-earnings-highlights-revenue-miss-eps-miss-ev-updates-automaker-says-2025-will-be-a-seminal">Tesla Q4 Earnings Highlights: Revenue Miss, EPS Miss, EV Updates, Automaker Says &#8216;2025 Will Be A Seminal Year&#8217;</a>
What's Next: Tesla has not shared a date for the opening of the California Supercharger location to date.
With a diner and drive-in movie theater, the location is likely to attract Tesla fans from around the world along with the loyal California Tesla owners.
Previous reports showed the diner could be connected to the Tesla mobile app, allowing a range of payment options. Tesla CEO Elon Musk also previously said that Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) would be accepted as a payment option at the diner, but that remains to be seen if it ends up true.
Musk's original vision for the Supercharger location was unveiled on social media in 2018 when he said it would house a 1950s-style diner with waiters on roller skates and a drive-in theater with screens showing scenes from the great movies.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44845458/tesla-top-10-shareholder-questions-investors-want-answers-on-fsd-cybercab-tariffs-brand-damage-and-more">Tesla Shareholders Demand Answers On Self-Driving, Cybercab, Tariffs, Brand Damage And More: Their Top 10 Questions Ranked</a></li>
</ul>
Photo: Courtesy Tesla Inc.

Restaurants

$DOGE

Tesla Drive-In Movie Theater, Diner Supercharger Location Could Be Close To Opening

Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) built an empire on magic — but Charlie Munger wasn't buying any of it.
In what turned out to be one of his final public interviews before his death in 2023, the longtime Berkshire Hathaway vice chair took a hard-nosed look at the entertainment giant during the <a href="https://youtu.be/0S_ex0_gL5g?si=QnGchMcEXS3afWX9">Daily Journal Corp.'s annual Q&amp;A session</a> — the same forum where Munger famously spoke off-the-cuff with brutal clarity.
He was asked whether <a href="https://www.benzinga.com/insights/options/25/04/44797845/looking-at-walt-disneys-recent-unusual-options-activity">Disney was still a good investment</a>.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
His response? First came the correction: "We've never owned Disney shares," Munger clarified.
CNBC's Becky Quick, who was moderating the session, responded, "That's my mistake."
But then Munger leaned in. "Disney is an interesting case. Practically every business that Disney has has gotten tougher than it used to be," he said. "Again — welcome to human life."
For Munger, Disney's problems weren't subtle. They were structural. He described the company's golden era with reverence — calling ESPN a "total gold mine" and reminding listeners that "The Lion King" once dominated Broadway.
"Disney once owned the world," he said.
Now? He said nearly every part of the company — from streaming to sports — is struggling. "How would you like running the sports, ESPN, now at Disney compared to its heyday? It's going to be way harder for them."
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
Then came the line that caught the most attention: "Movies look to me like it's going to be a bloodbath."
That wasn't hyperbole. It was Munger's long-held belief. Despite Berkshire's investment in Paramount, he admitted he'd avoided the movie industry entirely. "I've never made an investment in a movie business in any way, shape, or form. It always gives me the willies," he said. "I don't like the unions. I don't like the crazy agents. I don't like the goddamn crazy lawyers. I don't like the crazy movie stars."
That, in a nutshell, was Charlie Munger: <a href="https://www.benzinga.com/personal-finance/25/03/44438885/charlie-munger-told-a-20-year-old-that-getting-rich-through-investing-is-damn-near-impossible-and-you-might-need-10-million-in-the-bank">blunt, sharp, and completely </a>unmoved by Hollywood glamour.
"It may be a good place to make a living as an actor or writer," he added, "but it's a hard place to <a href="https://www.benzinga.com/personal-finance/25/03/44438885/charlie-munger-told-a-20-year-old-that-getting-rich-through-investing-is-damn-near-impossible-and-you-might-need-10-million-in-the-bank">make money if you're an investor.</a>"
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
That skepticism hasn't looked so far off. As of this month, Disney's stock sits at $84.81 — down roughly 24% from just a year ago. And over the past five years, it's fallen nearly 60% from its 2021 peak of $199.45. While analysts still see long-term potential, the reality is clear: this isn't the Disney of the glory days.
In the end, Munger's message wasn't just about Disney — it was about investing in a world that doesn't stay easy forever. "They went from triumphs around — marching, marching, marching," he said. "All of a sudden, on practically every front, it's more difficult."
Then he shrugged: "<a href="https://www.benzinga.com/personal-finance/25/04/44723566/charlie-munger-gave-his-no-1-tip-for-a-long-and-happy-life-avoid-crazy-at-all-costs-but-watch-out-crazy-is-way-more-common-than-you-think">Welcome to human life</a>."
And with that, the 99-year-old investor said more in a few minutes than most analysts write in a dozen reports.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/investing-in-the-midwest-why-multifamily-real-estate-is-a-winning-strategy">This investment company boasts a 33.85% internal rate of return (IRR) for its realized projects, allowing accredited investors to earn passive returns and avoid the headaches of being a landlord.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Charlie Munger Was Asked If Disney Was Still a Good Investment: 'They Once Owned the World, Now It's a Bloodbath — Welcome to Human Life'

Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) has outperformed the market over the past 20 years by 4.61% on an annualized basis producing an average annual return of 12.48%. Currently, Norfolk Southern has a market capitalization of $49.91 billion. 
Buying $100 In NSC: If an investor had bought $100 of NSC stock 20 years ago, it would be worth $1,042.32 today based on a price of $220.60 for NSC at the time of writing.
<h3>Norfolk Southern's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745361016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Norfolk Southern 20 Years Ago Would Be Worth Today

Steel Dynamics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) reported first-quarter financial results after the market close on Tuesday. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/04/n44937297/steel-dynamics-reports-first-quarter-2025-results">from the print</a>.
<ul>
<li>Q1 Revenue: $4.37 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $4.2 billion</li>
</ul>
<ul>
<li>Q1 EPS: $1.44, versus estimates of $1.38</li>
</ul>
Steel Dynamics shipped 3.5 million tons of steel during the first quarter and generated $230 million of operating income from its steel operations. The company reported $153 million in cash flow from operations, which was reduced by annual companywide retirement profit-sharing distributions of $165 million.
The company&#8217;s average external product selling price for steel operations decreased $13 sequentially to $998 per ton. Steel Dynamics noted that flat-rolled steel pricing rebounded from recent lows. Steel demand in the quarter was led by the energy, non-residential construction, automotive and industrial sectors.
Steel Dynamics repurchased $250 million worth of its common stock in the quarter and ended the period with total liquidity of $2.6 billion.
&#8220;Underlying steel demand improved in the&nbsp;first quarter&nbsp;as customer orders rebounded and backlogs increased throughout the quarter at our steel and steel fabrication operations. Steel prices improved throughout the quarter from the lows seen in the second half of 2024 as trade actions have seen imports decline from recent highs,&#8221; said Mark Millett, chairman and CEO of Steel Dynamics.&nbsp;
&#8220;We should see the benefit from these higher steel prices in the coming months, as lagging flat-rolled steel contracts roll. In combination with our ongoing value-added flat-rolled steel and aluminum expansion initiatives, there are firm drivers in place for our continued growth.&#8221;
Outlook: Steel Dynamics expects domestic steel consumption to be &#8220;solid&#8221; throughout 2025 and in the coming years. The company noted that it has seen some &#8220;uncertainty&#8221; from customers related to recent trade tensions. 
Despite the uncertainty from customers, Steel Dynamics expects demand for lower-carbon emission, U.S.-produced steel products combined with lower imports to support steel pricing and demand.
STLD Price Action: S<a href="http://benzinga.com/quote/stld">teel Dynamics shares</a> closed Tuesday up 3.38% at $117.39; after-hours, shares were up 1.80% at $119.50 at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44938718/enphase-energy-q1-earnings-revenue-miss-eps-miss-cautious-guidance-shares-sink">Enphase Energy Q1 Earnings: Revenue Miss, EPS Miss, Cautious Guidance, Shares Sink</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Chawranphoto">Chawranphoto</a>/Shutterstock.

Guidance

Commodities

STLD

Steel Dynamics Reports Q1 Earnings: Revenue Beat, EPS Beat, Improving Demand Drives 'Solid' Steel Consumption Forecast

CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) has outperformed the market over the past 10 years by 5.42% on an annualized basis producing an average annual return of 14.98%. Currently, CoStar Group has a market capitalization of $34.11 billion. 
Buying $100 In CSGP: If an investor had bought $100 of CSGP stock 10 years ago, it would be worth $404.13 today based on a price of $80.87 for CSGP at the time of writing.
<h3>CoStar Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745360114_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CSGP

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Timberland Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBK#NASDAQ">TSBK</a>) reported quarterly earnings of $0.85 per share. This is a 21.43 percent increase over earnings of $0.70 per share from the same period last year.

TSBK

Timberland Bancorp Q2 EPS $0.85 Up From $0.70 YoY

Throughout the last three months, 5 analysts have evaluated Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $19.6, a high estimate of $22.00, and a low estimate of $16.00. Experiencing a 2.0% decline, the current average is now lower than the previous average price target of $20.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1745359270_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Extreme Networks. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mike Genovese &#x7C;Rosenblatt &#x7C;Lowers &#x7C;Buy &#x7C; $18.00&#x7C;$22.00 &#x7C; 
&#x7C;Mike Genovese &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Buy &#x7C; $22.00&#x7C;$22.00 &#x7C; 
&#x7C;Eric Martinuzzi &#x7C;Lake Street &#x7C;Raises &#x7C;Hold &#x7C; $16.00&#x7C;$15.00 &#x7C; 
&#x7C;Mike Genovese &#x7C;Rosenblatt &#x7C;Raises &#x7C;Buy &#x7C; $22.00&#x7C;$21.00 &#x7C; 
&#x7C;Ryan Koontz &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $20.00&#x7C;$20.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Extreme Networks. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Extreme Networks compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Extreme Networks's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Extreme Networks's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Extreme Networks analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Extreme Networks</h2>
Extreme Networks Inc provides cloud networking solutions and industry services and support. Extreme designs, develops, and manufactures wired, wireless, and software-defined wide area-network (SD- WAN) infrastructure equipment, software and cloud-based network management solutions. The company's cloud solution is a single platform that offers unified network management of wireless access points, switches, and SD-WAN. The company operates in a single segment which develops and markets network infrastructure equipment. Roughly half of the firm's revenue is generated in the Americas, with the rest coming from Europe, the Middle East, Africa, and Asia-Pacific.
<h3>A Deep Dive into Extreme Networks's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Extreme Networks's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -5.74%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Extreme Networks's net margin is impressive, surpassing industry averages. With a net margin of 2.64%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Extreme Networks's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 17.59%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.69%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 4.52, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

EXTR

5 Analysts Assess Extreme Networks: What You Need To Know

7 analysts have shared their evaluations of Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.71, a high estimate of $65.00, and a low estimate of $54.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.16%. 
<img src="https://www.benzinga.com/files/images/story/2025/1745359260_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Bristol-Myers Squibb. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Amsellem &#x7C;Piper Sandler &#x7C;Announces &#x7C;Overweight &#x7C; $65.00&#x7C;- &#x7C; 
&#x7C;Carter Gould &#x7C;Cantor Fitzgerald &#x7C;Announces &#x7C;Neutral &#x7C; $55.00&#x7C;- &#x7C; 
&#x7C;Trung Huynh &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $54.00&#x7C;$60.00 &#x7C; 
&#x7C;Asad Haider &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $55.00&#x7C;$67.00 &#x7C; 
&#x7C;Mohit Bansal &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $62.00&#x7C;$60.00 &#x7C; 
&#x7C;Olivia Brayer &#x7C;Cantor Fitzgerald &#x7C;Raises &#x7C;Neutral &#x7C; $55.00&#x7C;$50.00 &#x7C; 
&#x7C;Andrew Baum &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $65.00&#x7C;$60.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bristol-Myers Squibb. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bristol-Myers Squibb compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Bristol-Myers Squibb's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Bristol-Myers Squibb's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BMY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bristol-Myers Squibb analyst ratings.</a>
<h2>Unveiling the Story Behind Bristol-Myers Squibb</h2>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
<h3>Bristol-Myers Squibb's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Bristol-Myers Squibb's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.54%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Bristol-Myers Squibb's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.58%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Bristol-Myers Squibb's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.43%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Bristol-Myers Squibb's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.08%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Bristol-Myers Squibb's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.13, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 7 Analysts Discuss Bristol-Myers Squibb Stock

11 analysts have shared their evaluations of Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $250.73, along with a high estimate of $300.00 and a low estimate of $170.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.62%. 
<img src="https://www.benzinga.com/files/images/story/2025/1745359250_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Analog Devices's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Tom O'Malley &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $170.00&#x7C;$240.00 &#x7C; 
&#x7C;Tore Svanberg &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $225.00&#x7C;$275.00 &#x7C; 
&#x7C;Christopher Danely &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $235.00&#x7C;$265.00 &#x7C; 
&#x7C;Rick Schafer &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $270.00&#x7C;$245.00 &#x7C; 
&#x7C;William Stein &#x7C;Truist Securities &#x7C;Raises &#x7C;Hold &#x7C; $248.00&#x7C;$230.00 &#x7C; 
&#x7C;Harlan Sur &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $300.00&#x7C;$280.00 &#x7C; 
&#x7C;Timothy Arcuri &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $300.00&#x7C;$275.00 &#x7C; 
&#x7C;Joe Quatrochi &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $240.00&#x7C;$220.00 &#x7C; 
&#x7C;Joseph Moore &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $250.00&#x7C;$248.00 &#x7C; 
&#x7C;David Williams &#x7C;Benchmark &#x7C;Raises &#x7C;Buy &#x7C; $275.00&#x7C;$245.00 &#x7C; 
&#x7C;David Williams &#x7C;Benchmark &#x7C;Announces &#x7C;Buy &#x7C; $245.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Analog Devices. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Analog Devices compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Analog Devices's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Analog Devices's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ADI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Analog Devices analyst ratings.</a>
<h2>Discovering Analog Devices: A Closer Look</h2>
Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.
<h3>Understanding the Numbers: Analog Devices's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Analog Devices faced challenges, resulting in a decline of approximately -3.56% in revenue growth as of 31 January, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Analog Devices's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 16.15%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Analog Devices's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.11%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.81%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Analog Devices's debt-to-equity ratio is below the industry average. With a ratio of 0.22, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Analog Devices Stock: Analyst Perspectives (11 Ratings)

In the preceding three months, 14 analysts have released ratings for Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Boyd Gaming, revealing an average target of $79.71, a high estimate of $88.00, and a low estimate of $72.00. Marking an increase of 2.28%, the current average surpasses the previous average price target of $77.93. 
<img src="https://www.benzinga.com/files/images/story/2025/1745359240_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Boyd Gaming among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brandt Montour &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $73.00&#x7C;$78.00 &#x7C; 
&#x7C;Stephen Grambling &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $72.00&#x7C;$75.00 &#x7C; 
&#x7C;Joseph Stauff &#x7C;Susquehanna &#x7C;Lowers &#x7C;Positive &#x7C; $75.00&#x7C;$77.00 &#x7C; 
&#x7C;Barry Jonas &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $85.00&#x7C;$92.00 &#x7C; 
&#x7C;Joseph Stauff &#x7C;Susquehanna &#x7C;Lowers &#x7C;Positive &#x7C; $77.00&#x7C;$79.00 &#x7C; 
&#x7C;Stephen Grambling &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $81.00&#x7C;$82.00 &#x7C; 
&#x7C;Brandt Montour &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $78.00&#x7C;$74.00 &#x7C; 
&#x7C;Steven Wieczynski &#x7C;Stifel &#x7C;Raises &#x7C;Hold &#x7C; $82.00&#x7C;$74.00 &#x7C; 
&#x7C;Daniel Politzer &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $88.00&#x7C;$82.00 &#x7C; 
&#x7C;Ben Chaiken &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $86.00&#x7C;$79.00 &#x7C; 
&#x7C;Barry Jonas &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $88.00&#x7C;$85.00 &#x7C; 
&#x7C;Joseph Stauff &#x7C;Susquehanna &#x7C;Raises &#x7C;Neutral &#x7C; $77.00&#x7C;$69.00 &#x7C; 
&#x7C;Joseph Greff &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $80.00&#x7C;$74.00 &#x7C; 
&#x7C;Brandt Montour &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $74.00&#x7C;$71.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Boyd Gaming. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Boyd Gaming compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Boyd Gaming's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Boyd Gaming's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BYD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Boyd Gaming analyst ratings.</a>
<h2>Discovering Boyd Gaming: A Closer Look</h2>
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. Midwest and South hold the key number of entertainment properties, and it generate the majority of sales for the company.
<h3>Boyd Gaming: A Financial Overview</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3M period, Boyd Gaming showcased positive performance, achieving a revenue growth rate of 9.06% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.38%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Boyd Gaming's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 10.61%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Boyd Gaming's ROA stands out, surpassing industry averages. With an impressive ROA of 2.69%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Boyd Gaming's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 2.49.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Boyd Gaming: Insights From 14 Analyst Reviews

14 analysts have shared their evaluations of Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $190.21, with a high estimate of $265.00 and a low estimate of $135.00. Highlighting a 9.82% decrease, the current average has fallen from the previous average price target of $210.93. 
<img src="https://www.benzinga.com/files/images/story/2025/1745359228_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Biogen is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $225.00&#x7C;$221.00 &#x7C; 
&#x7C;Matthew Harrison &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $152.00&#x7C;$157.00 &#x7C; 
&#x7C;Christopher Raymond &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $135.00&#x7C;$138.00 &#x7C; 
&#x7C;George Farmer &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Outperform&#x7C; $224.00&#x7C;$244.00 &#x7C; 
&#x7C;Evan Seigerman &#x7C;BMO Capital &#x7C;Lowers &#x7C;Market Perform &#x7C; $139.00&#x7C;$156.00 &#x7C; 
&#x7C;Matthew Harrison &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $157.00&#x7C;$192.00 &#x7C; 
&#x7C;Salveen Richter &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $245.00&#x7C;$281.00 &#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $225.00&#x7C;$231.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $145.00&#x7C;$160.00 &#x7C; 
&#x7C;Mohit Bansal &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $140.00&#x7C;$165.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Lowers &#x7C;Buy &#x7C; $241.00&#x7C;$300.00 &#x7C; 
&#x7C;Srikripa Devarakonda&#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $210.00&#x7C;$220.00 &#x7C; 
&#x7C;Sumant Kulkarni &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $265.00&#x7C;$298.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $160.00&#x7C;$190.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Biogen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Biogen's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Biogen analyst ratings.</a>
<h2>Get to Know Biogen Better</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>A Deep Dive into Biogen's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Biogen's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 2.87%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Biogen's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 10.86%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Biogen's ROE stands out, surpassing industry averages. With an impressive ROE of 1.61%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.95%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.4.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIIB

14 Analysts Have This To Say About Biogen

Health Care

Press Releases

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

General

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Comments

Lyell Immunopharma

Notizie

Ultime notizie per Lyell Immunopharma (NASDAQ:LYEL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO